Furthermore, when PBL from PD-patients were compared to controls, differences in DA signaling, including reduced DA content, impaired DAT immunoreactivity [28] and higher levels of dopamine D1-like and D2-like receptors, were observed [29]. This evidence concerns the gene SLC6A3 and Parkinson disease.